• 1
    Pope JE.The diagnosis and treatment of Raynaud's phenomenon: a practical approach.Drugs2007;67:51725.
  • 2
    Steen V, Denton CP, Pope JE, Matucci-Cerinic M.Digital ulcers: overt vascular disease in systemic sclerosis.Rheumatology (Oxford)2009;48 Suppl 3:iii1924.
  • 3
    Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al.EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR).Ann Rheum Dis2009;68:6208.
  • 4
    Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials1996;17:112.
  • 5
    Steen VD, Medsger TA Jr.The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.Arthritis Rheum1997;40:198491.
  • 6
    DerSimonian R, Laird N.Meta-analysis in clinical trials.Control Clin Trials1986;7:17788.
  • 7
    Higgins JP, Thompson SG.Quantifying heterogeneity in a meta-analysis.Stat Med2002;21:153958.
  • 8
    Blom-Bulow B, Oberg K, Wollheim FA, Persson B, Jonson B, Malmberg P, et al.Cyclofenil versus placebo in progressive systemic sclerosis: a one-year double-blind crossover study of 27 patients.Acta Med Scand1981;210:41928.
  • 9
    Correa MJ, Mariz HA, Andrade LE, Kayser C.Oral n-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial [abstract].Arthritis Rheum2010;62 Suppl:S242.
  • 10
    Beckett VL, Conn DL, Fuster V, Osmundson PJ, Strong CG, Chao EY, et al.Trial of platelet-inhibiting drug in scleroderma: double-blind study with dipyridamole and aspirin.Arthritis Rheum1984;27:113743.
  • 11
    Belch JJ, Madhok R, Shaw B, Leiberman P, Sturrock RD, Forbes CD.Double-blind trial of cl115,347, a transdermally absorbed prostaglandin e2 analogue, in treatment of Raynaud's phenomenon.Lancet1985;1:11803.
  • 12
    Lukac J, Rovensky J, Tauchmannova H, Zitnan D.Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.Drugs Exp Clin Res1985;11:65963.
  • 13
    Mohrland JS, Porter JM, Smith EA, Belch J, Simms MH.A multiclinic, placebo-controlled, double-blind study of prostaglandin e1 in Raynaud's syndrome.Ann Rheum Dis1985;44:75460.
  • 14
    Williams HJ, Furst DE, Dahl SL, Steen VD, Marks C, Alpert EJ, et al.Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis.Arthritis Rheum1985;28:30814.
  • 15
    Wollersheim H, Thien T, Fennis J, van Elteren P, van 't Laar A.Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon.Clin Pharmacol Ther1986;40:21925.
  • 16
    Meyrick Thomas RH, Rademaker M, Grimes SM, MacKay A, Kovacs IB, Cook ED, et al.Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.Br J Dermatol1987;117:23741.
  • 17
    McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF, et al.Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.Ann Rheum Dis1988;47:437.
  • 18
    Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, et al.Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.BMJ1989;298:5614.
  • 19
    Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP.Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.J Rheumatol1992;19:140714.
  • 20
    Lau CS, Belch JJ, Madhok R, Cappell H, Herrick A, Jayson M, et al.A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.Clin Exp Rheumatol1993;11:3540.
  • 21
    Black CM, Halkier-Sorensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, et al.Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.Br J Rheumatol1998;37:95260.
  • 22
    Vayssairat M.Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis: French microcirculation society multicenter group for the study of vascular acrosyndromes.J Rheumatol1999;26:21738.
  • 23
    Denton CP, Howell K, Stratton RJ, Black CM.Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study.Clin Exp Rheumatol2000;18:499502.
  • 24
    Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, et al.Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon: a randomized, controlled study.Clin Exp Rheumatol2001;19:5038.
  • 25
    Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al.Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.Arthritis Rheum2004;50:398593.
  • 26
    Marasini B, Massarotti M, Bottasso B, Coppola R, Papa ND, Maglione W, et al.Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon.Scand J Rheumatol2004;33:2536.
  • 27
    Fries R, Shariat K, von Wilmowsky H, Bohm M.Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.Circulation2005;112:29805.
  • 28
    Gliddon AE, Dore CJ, Black CM, McHugh N, Moots R, Denton CP, et al.Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.Arthritis Rheum2007;56:383746.
  • 29
    Abou-Raya A, Abou-Raya S, Helmii M.Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.J Rheumatol2008;35:18018.
  • 30
    Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, et al.MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.Arthritis Rheum2009;60:8707.
  • 31
    Fiori G, Galluccio F, Braschi F, Amanzi L, Miniati I, Conforti ML, et al.Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis.Clin Exp Rheumatol2009;27:514.
  • 32
    Herrick A, ven den Hoogen F, Gabrielli A, Tamimi N, Reid C, O'Connell D, et al.Modified-release sildenafil reduces Raynaud's attack frequency in systemic sclerosis [abstract].Arthritis Rheum2009;60 Suppl:S174.
  • 33
    Herrick AL, van den Hoogen F, Gabrielli A, Tamimi N, Reid C, O'Connell D, et al.Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.Arthritis Rheum2011;63:77582.
  • 34
    Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R, et al.Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.Rheumatology (Oxford)2010;49:24208.
  • 35
    Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al.Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.Ann Rheum Dis2011;70:328.
  • 36
    Seibold JR, Wigley FM, Schiopu E, Denton CD, Silver RM, Steen VD, et al.Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: a randomized, double-blind, placebo-controlled, multicenter study [abstract].Arthritis Rheum2011;63 Suppl:S968.
  • 37
    Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, et al.Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.Ann Intern Med1994;120:199206.
  • 38
    Roald OK, Seem E.Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.Br Med J1984;289:5779.
  • 39
    Galluccio F, Matucci-Cerinic M.Two faces of the same coin: Raynaud's phenomenon and digital ulcers in systemic sclerosis.Autoimmun Rev2011;10:2413.
  • 40
    Thompson AE, Shea B, Welch V, Fenlon D, Pope JE.Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.Arthritis Rheum2001;44:18417.
  • 41
    Rodeheffer RJ, Rommer JA, Wigley F, Smith CR.Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon.N Engl J Med1983;308:8803.
  • 42
    Walker K, Pope J.Treatment of systemic sclerosis (SSc) complications: what to use when first-line treatment fails. A consensus of SSc experts.Semin Arthritis Rheum2012;42:4255.
  • 43
    Botzoris V, Drosos AA.Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.Joint Bone Spine2011;78:3416.
  • 44
    Biondi ML, Marasini B, Bassani C, Agastoni A.Increased plasma endothelin levels in patients with Raynaud's phenomenon.N Engl J Med1991;324:113940.
  • 45
    Dhillon S.Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis.Drugs2009;69:200524.
  • 46
    Garcia de la Pena-Lefebvre P, Rodriguez Rubio S, Valero Exposito M, Carmona L, Gamir Gamir ML, Beltran Gutierrez J, et al.Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.Rheumatology (Oxford)2008;47:4646.
  • 47
    Fishman AP.Pulmonary hypertension: beyond vasodilator therapy.N Engl J Med1998;338:3212.
  • 48
    Bali SG, Aberer F, Kraenke B, Aberer E.Discontinuing long-term iloprost treatment for Raynaud's phenomenon and systemic sclerosis: a single center, randomized, placebo-controlled, double-blind study.Acta Derm Venereol2011;20:1321.
  • 49
    Ambach A, Seo W, Bonnekoh B, Gollnick H.Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase v inhibitor sildenafil.J German Soc Dermatol2009;7:88891.